Literature DB >> 11948617

Animal models of Parkinson's disease.

Ranjita Betarbet1, Todd B Sherer, J Timothy Greenamyre.   

Abstract

Animal models are important tools in experimental medical science to better understand pathogenesis of human diseases. Once developed, these models can be exploited to test therapeutic approaches for treating functional disturbances observed in the disease of interest. On the basis of experimental and clinical findings, Parkinson's disease (PD) was the first neurological disease to be modeled and, subsequently, to be treated by neurotransmitter replacement therapy. Agents that selectively disrupt or destroy catecholaminergic systems, such as reserpine, methamphetamine, 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine have been used to develop PD models. Recently, it has been found that agricultural chemicals, such as rotenone and paraquat, when administered systemically, can reproduce specific features of PD in rodents, apparently via oxidative damage. Transgenic animals that over-express alpha-synuclein are used to study the role of this protein in dopaminergic degeneration. This review critically discusses animal models of PD and compares them with characteristics of the human disease. Copyright 2002 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948617     DOI: 10.1002/bies.10067

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  147 in total

1.  Transcriptional analysis in the brain: trophin-induced hippocampal synaptic plasticity.

Authors:  Janet Alder; Smita Thakker-Varia; Ira B Black
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

2.  Natural toxins implicated in the development of Parkinson's disease.

Authors:  Mohamed Salama; Oscar Arias-Carrión
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

3.  Bacopa monnieri extract offsets rotenone-induced cytotoxicity in dopaminergic cells and oxidative impairments in mice brain.

Authors:  George K Shinomol; Rajeswara Babu Mythri; M M Srinivas Bharath
Journal:  Cell Mol Neurobiol       Date:  2011-12-10       Impact factor: 5.046

4.  Protective effect of Bu-7, a flavonoid extracted from Clausena lansium, against rotenone injury in PC12 cells.

Authors:  Bo-yu Li; Yu-he Yuan; Jin-feng Hu; Qing Zhao; Dong-ming Zhang; Nai-hong Chen
Journal:  Acta Pharmacol Sin       Date:  2011-10-03       Impact factor: 6.150

Review 5.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

6.  Stem cell grafting improves both motor and cognitive impairments in a genetic model of Parkinson's disease, the aphakia (ak) mouse.

Authors:  Jisook Moon; Hyun-Seob Lee; Jun Mo Kang; Junpil Park; Amanda Leung; Sunghoi Hong; Sangmi Chung; Kwang-Soo Kim
Journal:  Cell Transplant       Date:  2012-10-02       Impact factor: 4.064

7.  Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast.

Authors:  Cheryl Dixon; Neal Mathias; Richard M Zweig; Donnie A Davis; David S Gross
Journal:  Genetics       Date:  2005-03-02       Impact factor: 4.562

8.  Identification of zebrafish A2 adenosine receptors and expression in developing embryos.

Authors:  Wendy Boehmler; Jessica Petko; Matthew Woll; Colleen Frey; Bernard Thisse; Christine Thisse; Victor A Canfield; Robert Levenson
Journal:  Gene Expr Patterns       Date:  2008-12-03       Impact factor: 1.224

9.  HILAQ: A Novel Strategy for Newly Synthesized Protein Quantification.

Authors:  Yuanhui Ma; Daniel B McClatchy; Salim Barkallah; William W Wood; John R Yates
Journal:  J Proteome Res       Date:  2017-05-03       Impact factor: 4.466

Review 10.  Antioxidants in central nervous system diseases: preclinical promise and translational challenges.

Authors:  Chandrashekhar D Kamat; Sunyana Gadal; Molina Mhatre; Kelly S Williamson; Quentin N Pye; Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.